Cargando…
Identification of the Regulatory Role of lncRNA SNHG16 in Myasthenia Gravis by Constructing a Competing Endogenous RNA Network
Myasthenia gravis (MG) is an autoimmune disorder resulting from antibodies against the proteins at the neuromuscular junction. Emerging evidence indicates that long non-coding RNAs (lncRNAs), acting as competing endogenous RNAs (ceRNAs), are involved in various diseases. However, the regulatory mech...
Autores principales: | Wang, Jianjian, Cao, Yuze, Lu, Xiaoyu, Wang, Xiaolong, Kong, Xiaotong, Bo, Chunrui, Li, Shuang, Bai, Ming, Jiao, Yang, Gao, Hongyu, Yao, Xiuhua, Ning, Shangwei, Wang, Lihua, Zhang, Huixue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016163/ https://www.ncbi.nlm.nih.gov/pubmed/32059338 http://dx.doi.org/10.1016/j.omtn.2020.01.005 |
Ejemplares similares
-
Competitive endogenous RNA network and pathway-based analysis of LncRNA single-nucleotide polymorphism in myasthenia gravis
por: Wang, Tianfeng, et al.
Publicado: (2021) -
Identification of the regulatory role of lncRNA HCG18 in myasthenia gravis by integrated bioinformatics and experimental analyses
por: Li, Shuang, et al.
Publicado: (2021) -
Construction of a TF–miRNA–gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis
por: Bo, Chunrui, et al.
Publicado: (2021) -
Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis
por: Li, Shuang, et al.
Publicado: (2019) -
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis
por: Cao, Yuze, et al.
Publicado: (2017)